Angiotensin II inhibits chemokine CCL5 expression in vascular smooth muscle cells from spontaneously hypertensive rats

Hypertension Research

Volumn 34, Issue 12, 2011, Pages 1313-1320

  Yun, Young Hyun ^a   Kim, Hye Young ^b   Do, Byung Soo ^b   Kim, Hee Sun ^b  

^a Dong A University   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

12 lipoxygenase; angiotensin II; CCL5; vascular smooth muscle cell

Indexed keywords

ANGIOTENSIN II ANTAGONIST; HYDROXYICOSATETRAENOIC ACID; RANTES; SMALL INTERFERING RNA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ANGIOTENSIN II; ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; CHEMOKINE CCL5; ELECTROPHORETIC MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, SMOOTH MUSCLE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REAL-TIME POLYMERASE CHAIN REACTION; RNA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 82955195054     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.132     Document Type: Article

References (45)

1. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kB transcription factors. Circ Res 1999; 84: 695-703. (Pubitemid 29157337)
2. Kashiwagi M, Musutani K, Shinozaki M, Hirakata H. MCP-1 and RANTES are expressed in renal cortex of rats chronically treated with nitric oxide synthase inhibitor. Involvement in macrophage and monocyte recruitment. Nephron 2002; 92: 165-173. (Pubitemid 34983890)
3. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-1058. (Pubitemid 27386288)
4. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008; 52: 256-263.
5. Marchesi C, Paradis R, Schiffrin EL. Role of the rennin-angiotensin system in vascular inflammation. Trends Phamacol Sci 2008; 29: 367-374.
6. Pan Q, Yang XH, Cheng YX. Angiotensin ll stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling. Braz J Med Biol Res 2009; 42: 531-536.
7. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321-329. (Pubitemid 32424019)
8. Kim HY, Kang YJ, Song IH, Choi HC, Kim HS. Upregulation of interleukin-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 2008; 31: 515-523. (Pubitemid 351597506)
9. Ishibashi M, Hiasa KI, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocyte in hypertension-induced vascular inflammation and remodeling. Circ Res 2004; 94: 1203-1210. (Pubitemid 38659633)
10. Kim JH, Kang YJ, Kim HS. IL-8/CXCL8 upregulates 12-lipoxygenase expression in vascular smooth muscle cells from spontaneously hypertensive rats. Immune Netw 2009; 9: 106-113.
11. Capers IV Q, Alexander RW, Lou P, Leon HD, Wilcox JN, Ishizaka N, Howard AB, Robert Taylor W. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30: 1397-1402. (Pubitemid 27528081)
12. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995; 25: 155-161.
13. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert antiinflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042-1048. (Pubitemid 350166045)
14. Rodŕguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all. Am J Physiol 2004; 286: 606-616.
15. Dhungana S, Sharrack B, Woodroofe N. Cytokines and chemokines in idiopathic intracranial hypertension. Headache 2009; 49: 282-285.
16. Navrtilova Z. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 191-204.
17. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, Westwick J. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol 1997; 122: 749-757. (Pubitemid 27453102)
18. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671. (Pubitemid 20356243)
19. Dorfmü ller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, Capron F, Coulomb-Lherminé A, Marfaing-Koka A, Simonneau G, Emilie D, Humbert M. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 534-539. (Pubitemid 34165478)
20. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kB activation. Kidney Int 1998; 53: 1608-1615. (Pubitemid 28243743)
21. Shahrara S, Park CC, Temkin V, Jarvis JW, Volin MV, Pope RM. RANTESmodulates TLR-4-induced cytokine secretion in human peripheral blood monocytes. J Immunol 2006; 177: 5077-5087. (Pubitemid 44527578)
22. Tripathy D, Thirumangalakudi L, Grammas P. RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging 2010; 31: 8-16.
23. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-959. (Pubitemid 28503085)
24. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J. Angiotensin ll regulates the synthesis of proinflammatory cytokine and chemokines in the kidney. Kidney Int Suppl 2002; 82: 12-22.
25. Kim JH, Kim HS. Downregulation of angiotensin ll-induced 12-Lipoxygenase expression and cell proliferation in vascular smooth muscle cells from spontaneously hypertensive rats by CCL5. Korean J Physiol Pharmacol 2009; 13: 385-392.
26. Natarajan R, Gu JL, Rossi J, Gonzales N, Lanting L, Xu L, Nadler J. Elevated glucose and angiontensin II increase 12-lipoxygenase activity and expression in porcine aortic smooth muscle cells. Proc Natl Acad Sci USA 1993; 90: 4947-4951. (Pubitemid 23182952)
27. Kim JA, Gu JL, Natarajan R, Rerliner JA, Nadler JL. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells: evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 1995; 15: 942-948.
28. Sasaki M, Hori MT, Hino T, Golub MS, Tuck ML. Elevated 12-lipoxytenase activity in the spontaneously hypertensive rat. Am J Hypertens 1997; 10: 371-378. (Pubitemid 27195971)
29. Ortiz BD, Nelson PJ, Krensky AM. Switching gears during T-cell maturation: RANTES and late transcription. Immunol Today 1997; 18: 468-471. (Pubitemid 27441588)
30. Kumar D, Hosse J, Toerne C, Noessner E, Nelson PJ. JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP11. J Immunol 2009; 182: 1011-1020.
31. El Mabrouk M, Touyz RM, Schiffrin EL. Differential Ang ll-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR. Am J Physiol Heart Cir Physiol 2001; 281: 30-39.
32. Wolf G, Neilson EG. From converting enzyme inhibition to angiotensin ll receptor blockade: new insight on angiotensin ll receptor subtypes in the kidney. Exp Nephrol 1996; 4: 8-19. (Pubitemid 26421851)
33. Gallinat S, Busche S, Raizada MK, Sumners C. The angiotensin ll type 2 receptor: an enigma with multiple variations. Am J Physiol 2000; 278: 357-374.
34. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RAK, Thaiss F. Angiotensin ll activates nuclear transcription factor-kB through AT1 and AT2 receptors. Kidney Int 2002; 61: 1986-1995. (Pubitemid 34539316)
35. Gonzalez-Nunez D, Claria J, Rivera F, Poch E. Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension 2001; 37: 334-338. (Pubitemid 32199096)
36. Nozawa K, Tuck ML, Golub MS, Eggena P, Nadler JL, Stern N. Inhibition of the lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am J Physiol 1990; 259: 1774-1780.
37. Lee HM, Lee CK, Lee SH, Roh HY, Bae YM, Lee KY, Lim J, Park PJ, Park TK, Lee YL, Won KJ, Kim B. p38 mitogen-activated protein kinase contributes to angiotensin llstimulated migration of rat aortic smooth muscle cells. J Pharmacol Sci 2007; 105: 74-81. (Pubitemid 47463527)
38. Touyz RM, Mabrouk ME, He G, Wu XH, Schiffrin EL. Mitogen-activated protein/extracellular signal-regulated kinase inhibition attenuates angiotensin ll-mediated signaling and contraction in spontaneously hypertensive rat vascular smooth muscle cells. Cire Res 1999; 84: 505-515. (Pubitemid 29138587)
39. Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V, Schiffrin EL. Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens 2001; 19: 553-559. (Pubitemid 32280947)
40. Viedt C, Soto U, Krieger-brauer HI, Fei J, Elsing C, Kubler W, Kreuzer J. Differential activation of mitogen-activated protein kinase in smooth muscle cells by angiotensin ll: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 2000; 20: 940-948. (Pubitemid 30207566)
41. Zhao Y, Song HJ, Yun SH, Chae YJ, Jia H, Kim CH, Ha TS, Sachinidis A, Ahn HY, Davidge ST. Inhibition of angiotensin ll-induced vascular smooth muscle cell hypertrophy by different catechins. Korean J Physiol Pharmacol 2005; 9: 117-123. (Pubitemid 40704227)
42. Hamaguchi A, Kim S, Yano M, Yamanaka S, Iwao H. Activation of glomerular MAP kinases in Ang ll-mediated hypertension. J Am Soc Nephrol 1998; 9: 372-380. (Pubitemid 28122862)
43. Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H. Differential activation of cardiac c-Jun amino terminal kinase and ERK in Ang ll-mediated hypertension. Circ Res 1998; 83: 752-760. (Pubitemid 28462790)
44. Takahashi E, Berk BC. MAP kinases and vascular smooth muscle function. Acta Physiol Scand 1998; 164: 611-621. (Pubitemid 29015679)
45. Schmitz U, Berk BC. Ang ll signal transduction: stimulation of multiple MAP kinase pathways. Trends Endocrinol Metab 1997; 8: 261-266. (Pubitemid 27424202)